Most organizations believe their existing carrier vetting process demonstrates reasonable care. It does not, and the distance between what a company believes its process shows and what a plaintiff’s attorney, a jury, or a derivative suit will actually find is where the exposure lives.
That gap is not just an operational problem anymore. It is a governance problem. A board that has never asked whether its carrier selection process would survive discovery has not exercised the kind of informed oversight Caremark requires. A CFO who has not assessed whether this exposure is material has a disclosure question, whether or not anyone has framed it that way yet.
The Forensic Vetting Process℠
The conventional industry practice for vetting a carrier relies on six data points: certificate of insurance, CSA scores, FMCSA authority, the carrier agreement, a W-9, and operating authority type. That process was built for a legal environment that no longer exists, and it was never designed to answer a governance question. It was designed to satisfy an operational compliance checklist.
When this Framework℠ is in place, it does something boards and CFOs care about independent of the litigation question: it produces a risk profile that already exceeds Framework℠insurance underwriting requirements, which changes the cost and availability of coverage.
WHY THIS IS A BOARD-LEVEL QUESTION
A derivative suit following a catastrophic freight liability event does not ask whether the dispatcher made a good decision on a Friday afternoon. It asks whether the board had a system in place to know that decisions like that were being made responsibly, consistently, and in a documented way, across the organization.
That is the Caremark doctrine in practice: not perfection, but a good faith system of oversight. An organization with no documented carrier selection and dispatch protocol, and no record of the board or executive team having addressed the post-Montgomery landscape, has a harder time demonstrating that system exists.